NEW YORK (GenomeWeb News) – Pathwork Diagnostics today announced a deal to offer its Pathwork Tissue of Origin Test for cancer diagnosis in China.
The deal with Kindstar Global, which claims to be the largest esoteric diagnostic testing business in China, expands the Redwood City, Calif.-based company's international network of test and service providers, Pathwork said. The agreement is the first international in vitro diagnostic deal for the company, it added.
Kindstar will offer the IVD kit version of the Tissue of Origin Test, which is cleared by the US Food and Drug Administration and covered by Medicare.
The molecular diagnostic test uses a tumor's genomic information to help clinicians diagnose difficult cancers, such as those that are metastatic or have a complex clinical history, Pathwork said. It measures gene expression levels of 2,000 genes, and by using proprietary algorithms compares the tumor's gene expression pattern to that of 15 tumor types, representing 58 morphologies and 90 percent of all solid tumors.
"Having access to this test will allow us to expand the current testing services we offer Chinese physicians and position our business as the leading diagnostic company in the fastest growing market in the world," Kindstar Founder and CEO Shiang Huang said in a statement.
Financial and other terms of the deal were not disclosed.